Technical Momentum and Indicator Analysis
The stock closed at ₹112.40 on 17 Jul 2026, down 3.06% from the previous close of ₹115.95. Intraday volatility saw a high of ₹118.15 and a low of ₹111.70, reflecting some short-term selling pressure. However, the broader technical landscape reveals a more constructive outlook. The weekly MACD indicator remains bullish, signalling positive momentum over the medium term, while the monthly MACD is mildly bullish, indicating a gradual strengthening trend on a longer horizon.
Relative Strength Index (RSI) readings on both weekly and monthly charts currently show no clear signal, suggesting the stock is neither overbought nor oversold. This neutral RSI stance implies room for further price movement without immediate risk of reversal due to exhaustion.
Bollinger Bands present a mixed picture: weekly readings are mildly bullish, indicating price support near the lower band and potential for upward movement, whereas monthly bands are mildly bearish, reflecting some longer-term volatility and caution. Daily moving averages, however, are firmly bullish, reinforcing short-term upward momentum and suggesting that recent price dips may be temporary corrections within an overall positive trend.
The Know Sure Thing (KST) oscillator aligns with this view, showing bullish momentum on the weekly scale and mild bullishness monthly, further supporting the case for a sustained upward trajectory. Conversely, On-Balance Volume (OBV) indicators diverge slightly, with weekly OBV mildly bearish, hinting at some selling pressure, but monthly OBV remains bullish, indicating accumulation over the longer term.
Trend Assessment and Market Context
The technical trend for Themis Medicare has shifted from mildly bullish to bullish, reflecting an improvement in price momentum and investor confidence. Despite the Dow Theory indicating no clear trend on weekly and monthly scales, the combination of MACD, moving averages, and KST suggests a positive directional bias. This nuanced technical picture highlights the importance of monitoring volume and momentum indicators closely for confirmation of trend sustainability.
Comparing Themis Medicare’s returns with the Sensex reveals a mixed performance. Over the past week, the stock declined by 3.64%, contrasting with the Sensex’s 0.58% gain. However, over one month and year-to-date periods, Themis Medicare outperformed the benchmark significantly, delivering returns of 10.58% and 11.67% respectively, while the Sensex posted modest gains of 0.49% and a decline of 9.43%. This divergence underscores the stock’s potential for recovery and growth despite short-term volatility.
Longer-term returns tell a more cautious story. Over one year, Themis Medicare’s stock fell 9.61%, slightly worse than the Sensex’s 6.59% decline. Over three and five years, the stock underperformed the benchmark considerably, with returns of -25.18% and 28.21% compared to Sensex gains of 16.84% and 45.25% respectively. Yet, over a decade, Themis Medicare has delivered a robust 106.90% return, demonstrating resilience and growth potential in the longer term, albeit trailing the Sensex’s 177.29% gain.
Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!
- - Reliable Performer certified
- - Consistent execution proven
- - Large Cap safety pick
Moving Averages and Momentum Indicators: A Closer Look
The daily moving averages for Themis Medicare are bullish, indicating that the short-term price trend is upward. This is a critical signal for traders and investors looking for entry points, as it suggests that recent price declines may be temporary pullbacks within a broader uptrend. The bullish daily moving averages complement the weekly MACD’s positive momentum, reinforcing confidence in the stock’s near-term prospects.
The weekly MACD’s bullish stance is particularly significant as it reflects momentum over several weeks, signalling that buying interest is gaining traction. The monthly MACD’s mildly bullish reading suggests that while the longer-term trend is improving, it remains cautious, warranting close observation for confirmation of sustained strength.
Meanwhile, the KST oscillator’s bullish weekly and mildly bullish monthly readings add further weight to the positive momentum narrative. KST is a momentum indicator that aggregates multiple rate-of-change calculations, and its bullish readings imply accelerating price gains. This is a positive sign for investors seeking confirmation of trend strength beyond simple moving averages.
However, the divergence in OBV readings—weekly mildly bearish versus monthly bullish—indicates some short-term selling pressure amid longer-term accumulation. This suggests that while some investors may be taking profits or reducing exposure in the short term, institutional or longer-term investors could be accumulating shares, supporting the stock’s foundation for future gains.
Price Range and Volatility Considerations
Themis Medicare’s current price of ₹112.40 is well below its 52-week high of ₹147.99 but comfortably above its 52-week low of ₹65.00. This wide trading range reflects significant volatility over the past year, which may be attributed to sector-specific challenges and broader market conditions. The stock’s ability to maintain a level above ₹110 despite recent declines suggests a degree of price support, which technical indicators corroborate.
Today’s intraday range between ₹111.70 and ₹118.15 highlights ongoing price fluctuations, underscoring the importance of monitoring technical signals closely. Investors should be mindful of potential volatility while considering the bullish momentum signals that suggest a possible rebound or continuation of the upward trend.
Themis Medicare Ltd or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Mojo Score and Rating Upgrade
Themis Medicare currently holds a Mojo Score of 60.0, reflecting a moderate technical and fundamental standing within its sector. Notably, the company’s Mojo Grade was upgraded from Sell to Hold on 30 Jun 2026, signalling an improvement in its outlook. This upgrade aligns with the observed technical momentum shift from mildly bullish to bullish, suggesting that the stock may be stabilising after a period of underperformance.
As a micro-cap entity in the Pharmaceuticals & Biotechnology sector, Themis Medicare faces inherent volatility and sector-specific risks. However, the recent technical improvements and rating upgrade indicate that the stock is gaining traction and may offer opportunities for investors willing to navigate its risk profile.
Investor Takeaway and Outlook
In summary, Themis Medicare Ltd’s technical parameters have shifted favourably, with key indicators such as MACD, moving averages, and KST signalling bullish momentum. While short-term price declines and weekly OBV weakness suggest some caution, the overall technical trend upgrade and monthly bullish signals provide a constructive outlook.
Investors should weigh these technical signals alongside the stock’s mixed return performance relative to the Sensex, considering both the potential for recovery and the risks associated with its micro-cap status. The recent Mojo Grade upgrade to Hold further supports a cautious but optimistic stance.
Continued monitoring of volume trends, momentum oscillators, and price action will be essential to confirm the sustainability of this bullish shift. For those seeking exposure to the Pharmaceuticals & Biotechnology sector, Themis Medicare’s evolving technical profile merits attention as part of a diversified portfolio strategy.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
